What we found on the web about Eucreas
This category is for articles that have been tagged with the template {{R from brand ... Eucreas; Exanta; Exarta; F. Faslodex; Firazyr; Flagyl; Flexeril; Flexiril; Flubenol; Fluimucil
You are here: Home Reviews Eucreas (vildagliptin + metformine) Eucreas (vildagliptin + metformine) Eucreas (vildagliptin and metformine) is approved for treatment of type 2 ...
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com 1/3 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG ...
ZURICH, Feb 25 (Reuters) - The European Union approved Novartis's Eucreas diabetes pill, the Swiss drugmaker said on Monday, following its approval of Galvus, one of the ...
1. NAME OF THE MEDICINAL PRODUCT Eucreas 50 mg/850 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 50 mg of vildagliptin and 850 ...
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com 1/4 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG ...
Eucreas (yoo-kree-ass) is a medicine which is used in diabetes mellitus. Eucreas contains metformin hydrochloride/vildagliptin. It is supplied by Novartis Pharmaceuticals UK Ltd.
For multiple quantities, you can edit the amount after you click on Add to Cart. This item requires a prescription from your doctor. Manufacturer: Novartis
The information in this Medicine Guide for Eucreas varies according to the condition being treated and the particular preparation used. To select a preparation used in the ...
Eucreas tablets contain two active ingredients, metformin and vildagliptin. These are both medicines used to help control blood sugar levels in people with type 2 diabetes.
Here is what users have to say about Eucreas

{{drugbox | IUPAC_name = (S)-1-1pyrrolidine-2-carbonitrile |synonyms = (2S)-1-{2-2acetyl}pyrrolidine-2-carbonitrile | image = Vildagliptin Structural Formulae.png | width = 140 | CAS_number = 274901-16-5 | ATC_prefix = A10 | ATC_suffix = BH02 | ATC_supplemental =
ATC: BD08 (with metformin) | PubChem = 6918537 | DrugBank = | C = 17 |H = 25 |N = 3 |O = 2 | molecular_weight = 303.399 g/mol | bioavailability = 85% | protein_bound = 9.3% | metabolism = Mainly hydrolysis to inactive metabolite; CYP450 not appreciably involved | elimination_half-life = 2 to 3 hours | excretion = Renal | pregnancy_category = Not recommended | legal_UK = POM | legal_status = | routes_of_administration = Oral }} Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIPMentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. PMID 8100523. by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!